Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 20
2002 37
2003 32
2004 98
2005 163
2006 296
2007 237
2008 395
2009 465
2010 697
2011 526
2012 627
2013 618
2014 992
2015 1028
2016 949
2017 906
2018 1299
2019 1273
2020 1219
2021 1356
2022 1372
2023 1262
2024 1605
2025 2103
2026 1068

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20,643 results

Results by year

Filters applied: . Clear all
Page 1
Prehabilitation in cancer care: an evolving field.
Gaffney C, Gorzelitz J, Reeves J, Steffens D. Gaffney C, et al. BMC Cancer. 2026 Jun 26;26(1):776. doi: 10.1186/s12885-026-16404-5. BMC Cancer. 2026. PMID: 42363120 Free PMC article.
Prognostic value of circulating tumor DNA and copy-number alterations in patients receiving tandem [225Ac]Ac-/[177Lu]Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer: a prospective observational study.
Amghar M, Hielscher T, Rausch T, Özgür H, Bauder-Wüst U, Rathke H, Bruchertseifer F, Morgenstern A, Roscher M, Beneš V, Kratochwil C, Benešová-Schäfer M. Amghar M, et al. BMC Cancer. 2026 Aug 29;26(1):1038. doi: 10.1186/s12885-026-16791-9. BMC Cancer. 2026. PMID: 42681619 Free PMC article.
DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.
Grishina O, Schmoor C, Sellner C, Hackanson B, Mikesch JH, Deligiannis I, Thol F, Crysandt M, Junghanss C, Runde V, Rosée P, Teichmann LL, Al-Ali HK, Sauer T, Germing U, Griesinger F, Lukic S, Krauter J, Janjetovic S, Koch J, Staib P, Topaly J, de Wit M, Kraemer DM, Oelschläger L, Schnetzke U, Schmah O, Wessendorf S, Khandanpour C, Kündgen L, Schwalenberg M, Heuser M, Ganser A, Döhner H, Wäsch R, Lübbert M. Grishina O, et al. BMC Cancer. 2026 Aug 5;26(1):941. doi: 10.1186/s12885-026-16617-8. BMC Cancer. 2026. PMID: 42563153 Free PMC article. Clinical Trial.
20,643 results
You have reached the last available page of results. Please see the User Guide for more information.